Experience with hemoadsorption (CytoSorb®) in the management of septic shock patients

Figure 1 Comparison of percentage reduction in vasopressor doses among survivor and non-survivor patients.

Figure 2 Comparison of sepsis scores among survivor and non-survivor patients. Significant reduction in acute physiology and chronic health evaluation II (P < 0.0001) and sequential organ failure assessment (P = 0.0070) scores in survivor group. APACHE: Acute physiology and chronic health evaluation; SOFA: Sequential organ failure assessment.

Figure 3 Initiation of CytoSorb^® treatment after onset of septic shock. ICU: Intensive care units.

Figure 4 Length of patients’ stay in intensive care units (d). ICU: Intensive care units.